Horny goat weed carries a double authenticity burden. Like every single-marker botanical it attracts the ordinary economics of dilution and relabelling — and on top of that, the category it serves is shadowed by a genuinely criminal practice: undeclared synthetic PDE5 inhibitors spiked into finished vitality products. An ingredient buyer needs to understand both, because the second one shapes how regulators, retailers and customers will read the first.
Two Problems, One Category
Keep the two failure modes separate, because they have different perpetrators and different tests.
Extract-level adulteration is the familiar economics of botanicals: stretching real material with cheaper inputs, or dressing a lower grade up as a higher one. It is committed upstream, and it is caught by the classical analytical package.
Finished-product spiking is the addition of undeclared synthetic PDE5 inhibitors — sildenafil, tadalafil and a long tail of structural analogues designed to dodge standard screens — to finished vitality products so they "work". Regulators have pulled hundreds of such products from the US and EU markets over the years. This is done by bad actors at the formulation or contract-manufacturing stage; a botanical extract is the cover story, not the culprit. But every honest brand in the category inherits the scrutiny, which is why a documented clean supply chain is a commercial asset and not paperwork theatre.
Route 1 — Species Substitution and Undeclared Blends
The largest quiet problem in Epimedium. Dozens of Epimedium species exist beyond the pharmacopoeial handful, raw material is substantially wild-collected, and dried, milled aerial parts of related species are indistinguishable by eye. Blending cheaper or non-pharmacopoeial species into declared material moves cost, and because all of them contain some icariin-family flavonoids, a total-flavonoid assay stays plausible.
What catches it: a declared source species on the CoA plus the full component split — icariin, epimedins A/B/C, baohuoside I — which forms a species-characteristic fingerprint. A profile that wanders between batches while the headline assay holds is the classic signature of an undeclared blend. For raw-material-level certainty, HPTLC fingerprinting against reference species, or DNA barcoding of the herb before extraction, can be arranged.
Route 2 — Stem, Marc and Exhausted Material
Leaf is where the flavonoids live; stem carries far less. Milling stem in with leaf, or blending back extracted marc, adds weight that looks and smells right while diluting the actives.
What catches it: the HPLC assay itself — the actives simply are not there — supported by an aerial-part/leaf declaration and an acid-insoluble ash limit (NMT 2%), which also flags the soil carry-over typical of wild-collected mountain material.
Route 3 — Undeclared Carriers
Maltodextrin, dextrose and starch are legitimate, declared processing aids; the adulteration is the undeclared version used to make up weight in material sold as pure extract. The tells are a suspiciously pale colour, an off-pattern bulk density and a loss-on-drying figure that does not match the reference material.
What catches it: total and acid-insoluble ash for mineral bulking, and a specification that requires carriers declared by name and percentage on the CoA — which converts an omission into a falsification, a materially different decision for the supplier.
Route 4 — Total-Flavonoid Relabelling
The Epimedium-specific spec game, covered in depth in our standardisation guide: total-icariins material — legitimately assayed as the sum of five compounds — sold against a single-marker icariin specification, usually on the strength of a UV assay that cannot tell the difference. The buyer pays single-compound prices for a family total.
What catches it: HPLC by name in the specification, the compound and basis stated explicitly, and the component split reported. One resolved chromatogram ends the ambiguity.
Route 5 — Marker Spiking
The sophisticated end at extract level: lifting an assay with purified icariin — or, cruder, with anything that absorbs at the right wavelength when the buyer's method is UV. The material passes the stated test while the underlying extract is thinner than declared.
What catches it: the family profile again. Genuine Epimedium extract carries icariin with its epimedins in species-plausible proportions; an extract with a towering icariin peak and a hollow epimedin background is not something any plant produced. Nature is hard to counterfeit across five compounds at once.
And the Spiking Problem — What an Ingredient Buyer Should Do
Be clear about where the risk sits: sildenafil analogues appear in finished products, introduced downstream by bad actors — not in honestly traded botanical extracts. But your brand will be judged by category, not by intent. The defensible position is documented: a supplier CoA with a resolved HPLC chromatogram, an LC-MS/MS screen for sildenafil and its analogues on the ingredient (ours is available on request), your own finished-product screening at lot release, and a contract manufacturer who welcomes both. Keep every report; this is the file that answers a regulator, a retailer or a marketplace delisting inside a day.
Standard drug screens chase known molecules, which is why analogue-capable LC-MS/MS screening — run against the growing analogue libraries — is worth specifying over a basic sildenafil-only test.
The Testing Package That Covers It All
| Test | Catches | Method |
|---|---|---|
| Identity — corresponds to icariin | Non-Epimedium material | TLC |
| Icariin, dry basis | Stem/marc dilution, thin extracts | HPLC |
| Component split (epimedins A/B/C, baohuoside I) | Species blends, relabelling, marker spiking | HPLC |
| Source species declaration | Substitution — anchors the profile | Declaration + fingerprint |
| Total ash / acid-insoluble ash | Mineral bulking, soil carry-over | IP-2014 |
| Loss on drying | Water weight sold as extract | IP-2014 |
| Residual solvent | Poorly finished extraction | GC |
| Declared carrier / excipient line | Undeclared bulking | Documentation |
| PDE5-inhibitor screen (analogue-capable) | Category's headline risk, documented clean | LC-MS/MS |
| Heavy metals, aflatoxins, microbiology | Poor raw material and storage | ICP-MS, HPLC-FLD, USP |
Practical Steps for a Buyer
- Specify HPLC, the compound and the basis by name. The three highest-value words in an Epimedium specification are "icariin", "HPLC" and "dry basis".
- Ask for the component split and the species. Free if the supplier runs a real method; revealing if they resist.
- Require carriers declared by name and percentage.
- Set acid-insoluble ash at NMT 2%. Cheap, and doubly useful on wild-collected material.
- Screen the category risk. LC-MS/MS PDE5-analogue screening on the ingredient at qualification, and on your finished product at release.
- Third-party verify the first batch. Nominate Eurofins, SGS or Intertek for pre-shipment testing on a new supplier, and re-qualify periodically — supply chains drift.
SV Botanica confirms Epimedium identity by TLC and assays icariin and its family profile by HPLC on every batch, with the source species declared, acid-insoluble ash, residual solvent, aflatoxin, heavy-metal and microbiological panels on the Certificate of Analysis, and LC-MS/MS PDE5-inhibitor screening available on request. Buyers are welcome to nominate an independent laboratory for pre-shipment verification — see the supplier evaluation guide for how to structure that, or the product specification for the full parameter list.
Source Standardised Horny Goat Weed Extract from India
Icariin 10–60% by HPLC · species-declared Epimedium · PDE5-inhibitor screening available · CoA-backed · samples for qualified buyers